Literature DB >> 11448086

Suicide and schizophrenia.

S G Siris1.   

Abstract

Suicide and suicide attempts occur at a significantly greater rate in schizophrenia than in the general population. Common estimates are that 10% of people with schizophrenia will eventually have a completed suicide, and that attempts are made at two to five times that rate. Demographically associated with suicidality in schizophrenia are being young, being early in the course of the illness, being male, coming from a high socioeconomic family background, having high intelligence, having high expectations, not being married, lacking social supports, having awareness of symptoms, and being recently discharged from the hospital. Also associated are reduced self-esteem, stigma, recent loss or stress, hopelessness, isolation, treatment non-compliance and substance abuse. Clinically, the most common correlates of suicidality in schizophrenia are depressive symptoms and the depressive syndrome, although severe psychotic and panic-like symptoms may contribute as well. This review specifically explores the issue of depression in schizophrenia, in relation to suicide, by organizing the differential diagnosis of this state and highlighting their potentially treatable or correctable causes. This differential diagnosis includes both acute and chronic disappointment reactions, the prodrome of an acute psychotic episode, neuroleptic induced akinesia and akathisia, the possibility of direct neuroleptic-induced depression, negative symptoms of schizophrenia, and the possible co-occurrence of an independent depressive diathesis. The potential beneficial roles of 'atypical' antipsychotic agents, including both clozapine and more novel agents, and adjunctive treatment with other psychopharmacological medications are considered, and the important roles of psychosocial factors and interventions are recognized.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448086     DOI: 10.1177/026988110101500209

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  66 in total

Review 1.  Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options.

Authors:  Herbert Y Meltzer
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

2.  Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response.

Authors:  John Kasckow; Ian Fellows; Shahrokh Golshan; Ellen Solorzano; Thomas Meeks; Sidney Zisook
Journal:  Am J Geriatr Psychiatry       Date:  2010-09       Impact factor: 4.105

3.  The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.

Authors:  Robert R Conley; Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Bruce J Kinon
Journal:  Schizophr Res       Date:  2006-11-15       Impact factor: 4.939

Review 4.  Switching between second-generation antipsychotics: why and how?

Authors:  Monika Edlinger; Susanne Baumgartner; Nadja Eltanaihi-Furtmüller; Martina Hummer; W Wolfgang Fleischhacker
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Antecedents and patterns of suicide behavior in first-admission psychosis.

Authors:  Shelly Bakst; Jonathan Rabinowitz; Evelyn J Bromet
Journal:  Schizophr Bull       Date:  2009-03-09       Impact factor: 9.306

Review 6.  Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04       Impact factor: 5.270

7.  An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses.

Authors:  A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-02-18       Impact factor: 5.270

Review 8.  A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder.

Authors:  Ayal Schaffer; Erkki T Isometsä; Jean-Michel Azorin; Frederick Cassidy; Tina Goldstein; Zoltán Rihmer; Mark Sinyor; Leonardo Tondo; Doris H Moreno; Gustavo Turecki; Catherine Reis; Lars Vedel Kessing; Kyooseob Ha; Abraham Weizman; Annette Beautrais; Yuan-Hwa Chou; Nancy Diazgranados; Anthony J Levitt; Carlos A Zarate; Lakshmi Yatham
Journal:  Aust N Z J Psychiatry       Date:  2015-07-14       Impact factor: 5.744

9.  Professional service utilisation among patients with severe mental disorders.

Authors:  Marie-Josée Fleury; Guy Grenier; Jean-Marie Bamvita; Jean Caron
Journal:  BMC Health Serv Res       Date:  2010-05-27       Impact factor: 2.655

10.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.